Indications and uses
relieves occasional constipation generally produces bowel movement in 6-12 hours
relieves occasional constipation generally produces bowel movement in 6-12 hours
take preferably at bedtime or as directed by a doctor age starting dose maximum dose adults and children 12 years and older 2 - 3 teaspoons once a day 3 teaspoons twice a day children 6 to under 12 years 1 - 1 1/2 teaspoons once a day 1 1/2 teaspoons twice a day children 2 to under 6 years 1/2 - 3/4 teaspoon once a day 3/4 teaspoon twice a day children under 2 years ask a doctor ask a doctor
avoid excessive heat store at room temperature 15°- 30°C (59°- 86°F)
Drug Facts
Sennosides 8.8 mg
Laxative
noticed a sudden change in bowel habits that lasts over two weeks Ask a doctor before use if you have
taking any other drug. Take this product two or more hours before or after other drugs. Laxatives may affect how other drugs work. Ask a doctor or pharmacist before use if you are
ask a health professional before use. If pregnant or breast-feeding
In case of overdose, get medical help or contact a Poison Control Center right away. Keep out of reach of children.
| age | starting dose | maximum dose |
|---|---|---|
| adults and children 12 years and older | 2 - 3 teaspoons once a day | 3 teaspoons twice a day |
| children 6 to under 12 years | 1 - 1 1/2 teaspoons once a day | 1 1/2 teaspoons twice a day |
| children 2 to under 6 years | 1/2 - 3/4 teaspoon once a day | 3/4 teaspoon twice a day |
| children under 2 years | ask a doctor | ask a doctor |
cocoa distillate flavor, natural chocolate flavor, methylparaben, propylene glycol, propylparaben, purified water, sucrose
Call 1-800-645-2158
Distributed by: Rugby Laboratories 31778 Enterprise Drive Livonia, MI 48150
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 755277 | SENEXON 8.8 MG in 5 mL Oral Solution | PSN | 4 |
| 702311 | sennosides 8.8 MG in 5 mL Oral Solution | PSN | 4 |
| 755277 | sennosides, USP 1.76 MG/ML Oral Solution [Senexon] | SBD | 4 |
| 702311 | sennosides, USP 1.76 MG/ML Oral Solution | SCD | 4 |
| 755277 | Senexon 1.76 MG/ML Oral Solution | SY | 4 |
| 755277 | Senexon 8.8 MG per 5 ML Oral Solution | SY | 4 |
| 702311 | sennosides 8.8 MG per 5 mL Oral Syrup | SY | 4 |
| 702311 | sennosides, USP 26.4 MG per 15 ML Oral Solution | SY | 4 |
| 702311 | sennosides, USP 8.8 MG per 5 ML Oral Solution | SY | 4 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 17856-1000-1 | 2021-01-29 | C162847 | 48780-1 | ba0f9c33-298c-a910-e053-dadaa90a0b85 | Senexon ® |
| 17856-1000-5 | 2021-01-29 | C162847 | 48780-1 | ba0f9c33-298c-a910-e053-dadaa90a0b85 | Senexon ® |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17856-1000-1 | Senexon | 10 mL in 1 CUP, UNIT-DOSE | SYRUP | 10 | 4 | |
| 17856-1000-5 | Senexon | 5 mL in 1 CUP, UNIT-DOSE | SYRUP | 5 | 4 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17856-1000 | SENEXON (SENNOSIDES A AND B) SYRUP [ATLANTIC BIOLOGICALS CORPS] | 4 | Legacy NDC, 2 package rows | 20191019_90983cc4-04cf-4cfc-a705-5681b985e6a0.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 17856-1000-1 | ML - Milliliter | 17856-1000 | 9a51ee4f-a955-4207-9d53-35cf704a6eab | 1 | 2015-10-02 |
| 17856-1000-5 | ML - Milliliter | 17856-1000 | d2e2ae32-55f2-4fe4-a60c-d79f0dc25961 | 1 | 2015-10-02 |
| 0536-1000-59 | ML - Milliliter | 0536-1000 | 2e54b885-8e67-46a0-ac59-75c50865a79f | 1 | 2013-05-02 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Sennosides A and B | ACTIVE INGREDIENT | 1B5FPI42EN | 2 | |
| Sennosides A and B | ACTIVE MOIETY | 1B5FPI42EN | 2 | |
| COCOA | INACTIVE INGREDIENT | D9108TZ9KG | 2 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 2 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 2 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 17856-1000 | 17856-1000-1, 17856-1000-5 |
| 0536-1000 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Sennosides A and B | 1B5FPI42EN | ACTIB |
| Methylparaben | A2I8C7HI9T | IACT |
| propylene glycol | 6DC9Q167V3 | IACT |
| propylparaben | Z8IX2SC1OH | IACT |
| water | 059QF0KO0R | IACT |
| cocoa | D9108TZ9KG | IACT |
| sucrose | C151H8M554 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION, CONCENTRATE / ORAL | 1 mg/1ml | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | GEL / VAGINAL | 2 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION/ DROPS / OPHTHALMIC | 0.05 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAVENOUS | 0.13 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL / OPHTHALMIC | 0.44 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION/ DROPS / OPHTHALMIC | 0.01 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / ORAL | 22602 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SOLUTION / INTRAMUSCULAR | 5 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / AURICULAR (OTIC) | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / OPHTHALMIC | 1 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CREAM, AUGMENTED / TOPICAL | 2 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / TOPICAL | 0.24 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SHAMPOO, SUSPENSION / TOPICAL | 2 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM / BUCCAL | 1.48 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION, EXTENDED RELEASE / ORAL | 40 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / NASAL | 140 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRAVENOUS | 95 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | FILM / BUCCAL | 1 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | OINTMENT / TOPICAL | 0.2 %w/w | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | AEROSOL, FOAM / TOPICAL | 0.04 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, CHEWABLE / ORAL | 1.28 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE / ORAL | 1072 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LIQUID / ORAL | 162 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / TOPICAL | 8 %w/w | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | POWDER / ORAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | JELLY / TOPICAL | 20 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | OINTMENT / OPHTHALMIC | 0.05 %w/w | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / EPIDURAL | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / TOPICAL | 420 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CAPSULE / ORAL | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | GEL / TOPICAL | 24 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / RECTAL | 0.02 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | PASTE, DENTIFRICE / DENTAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | PASTE, DENTIFRICE / DENTAL | 0.05 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IRRIGATION | 2 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / OPHTHALMIC | 1.5 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CAPSULE, EXTENDED RELEASE / ORAL | 0.22 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CREAM / TOPICAL | 6 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LOTION / TOPICAL | 351 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / NASAL | 250 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM, AUGMENTED / TOPICAL | 2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / RESPIRATORY (INHALATION) | 0.01 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / INTRAMUSCULAR | 0.02 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 0.8 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUPPOSITORY / VAGINAL | 252 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | TABLET, COATED / ORAL | 0.8 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ELIXIR / ORAL | 800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRALESIONAL | 0.02 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 9d88570f-1711-4b81-9fb4-272bd5695aa2 | 90983cc4-04cf-4cfc-a705-5681b985e6a0 | 2019-10-18 | Warnings | 9d88570f-1711-4b81-9fb4-272bd5695aa2 90983cc4-04cf-4cfc-a705-5681b985e6a0 |
Adverse event summaries are temporarily unavailable. Other product information remains available.